close

Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of peptide, peptide mimetic, and small molecule agonist compounds with a focus on melanocortin (MC) and natriuretic peptide receptor systems in the United States. The company's products in development include PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of heart failure, including chronic heart failure and acute heart failure, as well as for the treatment of difficult-to-control hypertension, including dialysis patients with hypertension; Bremelanotide, a peptide melanocortin receptor agonist, for prevention of organ damage secondary to cardiac surgery and related indications; and PL-6983, a peptide melanocortin receptor agonists, for treatment of female sexual dysfunction. Its products in development also comprise melanocortin receptor-based compounds for treatment of obesity and related metabolic syndrome; and NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection. Palatin Technologies has a licensing and research collaboration agreement with AstraZeneca AB to discover, develop, and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes, and related metabolic syndrome. The company was founded in 1986 and is based in Cranbury, New Jersey.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	0.60
Volume	6074
Volume Avg	83214
52 Week High	1.38
52 Week Low	0.39
PE	N/A
PE (group average)	39
EPS Year	-0.41
EPS change Q/Q	-88.89%
EPS change Q/Q Yr ago	-15%
EPS change Q/Q next Q est	-88.89%
EPS change Y/Y	-1000%
REV change Q/Q	-90%
REV change Q/Q Yr ago	-96.15%
EPS next Q est	-0.09
EPS next Y est	-0.22
Divident Annual	0.00
Dividend Yield	0%